Skip to main content
. 2012 Jul 21;260(1):122–130. doi: 10.1007/s00415-012-6599-y

Table 5.

Clinical outcomes during the observation period in both groups

Cilostazol (n = 101) Control (n = 107) p value*
Ischemic stroke 4 (4.0 %) 5 (4.7 %) >0.999
Transient ischemic attack 1 (1.0 %) 2 (1.9 %) >0.999
Angina or myocardial infarction 6 (5.9 %) 1 (0.9 %) 0.059
Major bleedinga 0 (0.0 %) 1 (0.9 %) >0.999

* p values are for Fisher’s exact test

aHemorrhagic stroke and hemorrhage requiring hospital admission and/or transfusion